HUTCHMED (China) Limited (HCM) RNS Announcements

Add to Alert list
Date Time Source Announcement
23 Nov 2016 07:34 AM
RNS
Director's Share Dealing
23 Nov 2016 07:30 AM
RNS
Chi-Med to Present Data at the 17th WCLC
23 Nov 2016 07:08 AM
RNS
Chi-Med to Present Data at the at the 17th WCLC
14 Nov 2016 09:06 AM
RNS
Chi-Med Presents Ph I Clinical Data for HMPL-523
01 Nov 2016 02:57 PM
RNS
Director's Share Dealing
31 Oct 2016 07:00 AM
RNS
Joint Venture - US$59.5m Land Compensation Payment
12 Oct 2016 07:00 AM
RNS
Director's Share Dealing
09 Aug 2016 08:07 AM
RNS
Director's Share Dealing
02 Aug 2016 08:18 AM
RNS
Change of Non-executive Directors
02 Aug 2016 07:00 AM
RNS
Chi-Med 2016 Interim Results
01 Aug 2016 07:21 AM
RNS
Chi-Med and AstraZeneca to Accelerate Savolitinib
05 Jul 2016 07:00 AM
RNS
Chi-Med to Announce 2016 HY Financial Results
29 Jun 2016 07:00 AM
RNS
Blocklisting Six Monthly Return
20 Jun 2016 07:00 AM
RNS
Savolitinib Global Phase II Trial Initiated
15 Jun 2016 08:09 AM
RNS
Additional Listing
31 May 2016 07:00 AM
RNS
Total Voting Rights
13 May 2016 07:00 AM
RNS
Enrollment completion of Phase III fruquintinib
29 Apr 2016 07:00 AM
RNS
Total Voting Rights
27 Apr 2016 01:12 PM
RNS
Results of Annual General Meeting
13 Apr 2016 04:23 PM
RNS
Exercise of Overallotment Option
12 Apr 2016 07:00 AM
RNS
Clinical trial of novel PI3K inhibitor HMPL-689
31 Mar 2016 07:00 AM
RNS
Total Voting Rights
29 Mar 2016 08:00 AM
RNS
Director/PDMR Shareholding
23 Mar 2016 10:34 AM
RNS
Holding(s) in Company
22 Mar 2016 02:00 PM
RNS
Closing of U.S. Public Offering of ADSs
21 Mar 2016 08:54 AM
RNS
Director/PDMR Shareholding
21 Mar 2016 07:00 AM
RNS
Sulfatinib Phase III registration study
18 Mar 2016 04:18 PM
RNS
Final Prospectus
17 Mar 2016 07:00 AM
RNS
Pricing of U.S. Public Offering of ADSs
15 Mar 2016 07:00 AM
RNS
2015 Annual Report and Notice of AGM
07 Mar 2016 07:59 AM
RNS
Fifth Filing of Form F-1 Registration Statement
04 Mar 2016 06:12 PM
RNS
Launch of Potential U.S. Public Offering of ADSs
04 Mar 2016 05:54 PM
RNS
Fifth Filing of Form F-1 Registration Statement
02 Mar 2016 07:00 AM
RNS
Sulfatinib Phase II initation in thyroid cancer
01 Mar 2016 07:00 AM
RNS
Final Results
11 Feb 2016 05:39 PM
RNS
Public Filing of Form F-1 Registration Statement
29 Jan 2016 08:03 AM
RNS
Notice of Results
15 Jan 2016 07:02 AM
RNS
Chi-Med initiates HMPL-523 Phase I clinical trial
29 Dec 2015 07:43 AM
RNS
Blocklisting Six Monthly Return
18 Dec 2015 07:00 AM
RNS
Initiation sulfatinib Phase III registration study
09 Dec 2015 07:00 AM
RNS
US$105 m Shanghai land compensation agreement
08 Dec 2015 07:00 AM
RNS
Initiation of fruquintinib Phase 3 trial in NSCLC
13 Nov 2015 02:50 PM
RNS
Second Public Filing of Registration Statement
10 Nov 2015 01:13 PM
RNS
Results of Extraordinary General Meeting
09 Nov 2015 07:59 AM
RNS
Director/PDMR Shareholding
06 Nov 2015 07:00 AM
RNS
Chi-Med initiates sulfatinib U.S. clinical trials
30 Oct 2015 07:00 AM
RNS
Clinical results presented
30 Oct 2015 07:00 AM
RNS
Total Voting Rights
30 Oct 2015 07:00 AM
RNS
Completion of Phase I clinical trial of HMPL 523
23 Oct 2015 07:00 AM
RNS
Milestone Payment from Lilly Triggered

Hutchmed China  Limited develops, manufactures, and sells pharmaceutical products. The Company offers drugs for oncology and autoimmune diseases treatment. HUTCHMED (China) is headquartered in Hong Kong and markets its products worldwide.

It was founded in 2000 and listed in London in 2018 under the ticker HCM. 

UK 100

Latest directors dealings